<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02023567</url>
  </required_header>
  <id_info>
    <org_study_id>2013CB531305</org_study_id>
    <nct_id>NCT02023567</nct_id>
  </id_info>
  <brief_title>Objective Diagnostic Markers and Personalized Intervention in MDD Patients</brief_title>
  <official_title>The Establishment of the Objective Diagnostic Markers and Personalized Medical Intervention in Patients With Major Depressive Disorders (MDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Anding Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalian Seventh People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major depressive disorder (MDD) is one of the most common psychiatric disorders, with high&#xD;
      recurrence rate, suicide rate and disability rate. It's reported that the global burden&#xD;
      caused by MDD will be up to the second rank among all the disease burdens by 2020. China is&#xD;
      also confronted with the daunting challenges against MDD. It's assessed that the monthly&#xD;
      incidence of MDD is 6.1%, non-hospitalizing rate reaches up to 92% and the non-treatment rate&#xD;
      is approximate 95%. However, to date, the pathogenesis of MDD is obscure and the current&#xD;
      therapies don't work well. Therefore, it's urgent and critical to elucidate the pathogenesis&#xD;
      of MDD, to develop early diagnostic criteria and effective intervention in MDD. Considering&#xD;
      the diversity of weights on genetic factor and environmental factor in MDD, in this project,&#xD;
      the investigators aim firstly to explore the effect of &quot;genetic-environmental interaction&quot;on&#xD;
      the pathogeny of MDD for classifying MDD into &quot;genetic type&quot;, &quot;environmental type&quot; and&#xD;
      &quot;others&quot; based on a case-control study. We next conduct the neurobiological, neurocognitive&#xD;
      and psycho-behavioral assessments among MDD, schizophrenia and healthy groups to screen the&#xD;
      salient endophenotypes for establishing the diagnostic models of MDD . The investigators&#xD;
      further analyse the changes of these indicators after 8 weeks'medication to select the&#xD;
      potential predictors for therapeutic evaluations and interventional options in MDD patients.&#xD;
      Finally, the investigators continue a 2-year follow-up study to test and verify the&#xD;
      predictors of prognosis in MDD patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The changes of HAMD total score at 8 weeks from baseline</measure>
    <time_frame>week 0,2,4,8</time_frame>
    <description>The scores are assessed at 0,2,4,8 weeks since the medication begins for MDD group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes of HAMA total score at 8 weeks from baseline</measure>
    <time_frame>week 0,2,4,8</time_frame>
    <description>The scores are assessment at 0,2,4,8 weeks since the medication begins for MDD group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of CGI score at 8 weeks from baseline</measure>
    <time_frame>week 0,2,4,8</time_frame>
    <description>The scores are assessment at 0,2,4,8 weeks since the medication begins for MDD group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The prognosis after the intervention</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with serious and non-serious adverse events</measure>
    <time_frame>Up to two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>MDD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drugs: SSRIs fluoxertine hydrochloride (20- 60m/day),paroxetine hydrochloride (20- 60m/day),sertraline hydrochloride (50- 200m/day),citalopram (20-60m/day), escitalopram (10-20mg/day),fluvoxamine (50-300mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group just receive baseline evaluation and did not receive any intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSRIs</intervention_name>
    <description>fluoxertine hydrochloride 20-60mg/day, paroxetine hydrochloride 20-60mg/day, sertraline hydrochloride 50-200mg/day, citalopram 20-60mg/day, escitalopram 10-20mg/day, fluvoxamine 50-300mg/day</description>
    <arm_group_label>MDD group</arm_group_label>
    <other_name>selective serotonin reuptake inhibitors</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. For MDD group:&#xD;
&#xD;
             Inclusion criteria:&#xD;
&#xD;
               -  Age between 18-55, male or female;&#xD;
&#xD;
               -  The diagnosis of MDD consistent with DSM-IV (M.I.N.I)&#xD;
&#xD;
               -  First-episode or relapsed;&#xD;
&#xD;
               -  Certain ability of reading and writing to complete the questionnaire survey and&#xD;
                  psychological assessment.&#xD;
&#xD;
               -  All participants provide written confirmation of informed consent prior to&#xD;
                  engaging the study protocol.&#xD;
&#xD;
             Exclusion criteria:&#xD;
&#xD;
               -  Current psychopathology or a history of neurologic conditions, including&#xD;
                  alcohol/substances dependence, the diagnosis of cognition impairment;&#xD;
&#xD;
               -  Severe somatic diseases, such as severe cardio-cerebral vascular diseases,&#xD;
                  respiratory diseases, liver diseases, kidney diseases, or malignant tumors;&#xD;
&#xD;
               -  Not signed the informed consent;&#xD;
&#xD;
               -  Been engaging other studies.&#xD;
&#xD;
          2. For Healthy control group&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  age between 18 and 55 years at the time of enrollment;&#xD;
&#xD;
          -  providing written confirmation of informed consent prior to engaging the study.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  lifetime or current diagnosis of any mental diseases;&#xD;
&#xD;
          -  severe somatic diseases, such as severe cardio-cerebral vascular diseases, respiratory&#xD;
             diseases, liver diseases, kidney diseases, or malignant tumors;&#xD;
&#xD;
          -  not signed the informed consent;&#xD;
&#xD;
          -  been engaging other studies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Sixth Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tianmei Si, MD</last_name>
    <phone>86-10-62723748</phone>
    <phone_ext>86-139109877</phone_ext>
    <email>si.tian-mei@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gang Wang, MD</last_name>
    <email>gangwangdoc@mail1.bbuser.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Anding Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Wang</last_name>
      <phone>86-13911695727</phone>
      <email>gangwangdoc@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Changqing Hu</last_name>
      <phone>86-13661106500</phone>
      <email>coannhu@126.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking University Sixth Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Liu</last_name>
      <phone>86-10-82801955</phone>
      <phone_ext>86-13671013073</phone_ext>
      <email>liu_qee@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hebei Medical University First Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dalian Seventh People's Hospital</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Anding Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>December 15, 2013</study_first_submitted>
  <study_first_submitted_qc>December 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2013</study_first_posted>
  <last_update_submitted>May 18, 2016</last_update_submitted>
  <last_update_submitted_qc>May 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Xin Yu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>After enrollment completion,we will decided whether share data or not.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

